Oncogenic Ki-ras inhibits the expression of interferon-responsive genes through inhibition of STAT1 and STAT2 expression

被引:62
作者
Klampfer, L
Huang, J
Corner, G
Mariadason, J
Arango, D
Sasazuki, T
Shirasawa, S
Augenlicht, L
机构
[1] Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA
[2] Int Med Ctr Japan, Res Inst, Shinjuku Ku, Tokyo 1628655, Japan
关键词
D O I
10.1074/jbc.M304721200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Endogenous interferon gamma (IFNgamma) promotes the host response to primary tumors, and IFNgamma-insensitive tumors display increased tumorigenicity and can evade tumor surveillance mechanisms. Here we demonstrate that activating mutations of Ki-ras are sufficient to inhibit the expression of STAT1 and STAT2, transcription factors required for signaling by IFNs, providing a potential mechanism for the insensitivity of tumors to IFNs. We demonstrated that colon cancer cell lines with Ki-ras mutations display reduced expression of IFN-responsive genes compared with the cell lines that have retained wild type Ras and that inactivation of the mutant Ki-ras allele in the HCT116 colon cancer cell line is sufficient to restore the expression of STAT1, STAT2, and IRF-9. Accordingly, the expression of 27 interferon-inducible genes was reduced in HCT116 cells compared with the isogenic clones with targeted deletion of the mutant Ki-ras allele, Hkh2 and Hke-3. The expression of IFNgamma receptors did not differ among the isogenic cell lines. IFNgamma stimulated transcription of a STAT1-dependent reporter gene was impaired by RasV12, demonstrating a transmodulation of IFN/STAT signaling by activated Ras. Finally, we demonstrated that the expression of RasV12 in 293T cells is sufficient to inhibit the endogenous expression of STAT1 and STAT2, confirming the negative regulation of IFN signaling by oncogenic Ras. Our data demonstrate that the signaling initiated by activated Ki-ras interferes with the IFN/STAT signaling pathway and modulates the responsiveness of cancer cells to interferons. Furthermore, the data suggest that tumors harboring activating Ki-ras mutations may escape tumor surveillance mechanisms due to reduced responsiveness to IFNgamma.
引用
收藏
页码:46278 / 46287
页数:10
相关论文
共 81 条
[1]   Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line [J].
Abril, E ;
Real, LM ;
Serrano, A ;
Jimenez, P ;
García, A ;
Canton, J ;
Trigo, I ;
Garrido, F ;
Ruiz-Cabello, F .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (02) :113-120
[2]  
ANWAR K, 1992, CANCER RES, V52, P5991
[3]  
BILLARD C, 1986, BLOOD, V67, P821
[4]  
Bluyssen Hans A. R., 1996, Cytokine and Growth Factor Reviews, V7, P11, DOI 10.1016/1359-6101(96)00005-6
[5]   Stat2 is a transcriptional activator that requires sequence-specific contacts provided by Stat1 and p48 for stable interaction with DNA [J].
Bluyssen, HAR ;
Levy, DE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (07) :4600-4605
[6]  
Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505
[7]   Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma [J].
Bromberg, JF ;
Horvath, CM ;
Wen, ZL ;
Schreiber, RD ;
Darnell, JE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7673-7678
[8]  
Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO
[9]  
2-0
[10]   Increasing complexity of Ras signaling [J].
Campbell, SL ;
Khosravi-Far, R ;
Rossman, KL ;
Clark, GJ ;
Der, CJ .
ONCOGENE, 1998, 17 (11) :1395-1413